Clinical Trials · NCT00402077

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Name: A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Pramlintide

Phase: Phase 2
Recruitment status: Completed
Sponsor: AstraZeneca
Enrollment: 258
Start date: Nov 2006
Locations: 16 sites, United States
Primary endpoint: All treatment-emergent adverse events occurring during the 24-week treatment period

View Pramlintide compound reference